The Test Your Annual Physical Doesn't Order (But Should)

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

The standard metabolic panel measures glucose. Fasting glucose has been the clinical marker of choice for glycemic assessment since the 1970s. It appears on every basic metabolic panel. It generates a normal-range result in a man who has had insulin resistance for a decade. The insulin resistance is there. The glucose compensation is working. The test reports: normal.

The Sequence Standard Testing Misses

Insulin resistance develops through a predictable sequence. Understanding the sequence explains why fasting glucose arrives late.

Stage 1: Peripheral insulin resistance develops. Cells in muscle, liver, and fat tissue become progressively less responsive to insulin’s signal. Insulin binds to its receptor but produces a diminished cellular response. Glucose uptake slows.

Stage 2: The pancreas compensates. The beta cells of the pancreas detect elevated blood glucose and respond by producing more insulin. For years, sometimes a decade, the increased insulin production is sufficient to maintain fasting glucose in the normal range.

During this stage: fasting glucose is normal. Fasting insulin is elevated. The standard metabolic panel reports: normal. The compensation is working. But the higher circulating insulin itself is not metabolically neutral.

Stage 3: Compensation fails. After years of chronic beta cell stress, insulin secretion capacity begins to decline. The fasting glucose rises. The standard metabolic panel detects the problem. This is when prediabetes is diagnosed.

Fasting insulin identifies the compensation at Stage 2. Fasting glucose identifies the failure at Stage 3. The clinical window between these stages is the most important and most missed opportunity for cardiovascular risk modification.

What Elevated Insulin Does to the Cardiovascular System

During the compensatory phase, elevated circulating insulin is not benign. It produces four primary cardiovascular effects.

Sodium Retention and Blood Pressure

Insulin has direct renal effects, promoting sodium and water retention through stimulation of sodium channels in the collecting duct. Chronic hyperinsulinemia produces a volume-expanded state that elevates blood pressure independent of sodium intake. This is one mechanism by which insulin resistance drives hypertension before glucose becomes abnormal. 4 / Promising

The man with a fasting insulin of 18 and a borderline blood pressure of 132/84 may be exhibiting insulin-mediated volume expansion, not primary essential hypertension. Treating the blood pressure without addressing the insulin resistance treats the downstream consequence while leaving the upstream driver in place.

Atherogenic Lipid Pattern

Chronic hyperinsulinemia promotes hepatic production of VLDL particles. VLDL is the precursor of LDL. High VLDL production floods the bloodstream with triglyceride-rich particles. Lipoprotein lipase clears the triglycerides from these particles, producing a residual small, dense LDL particle. This is the atherogenic lipid phenotype: elevated triglycerides, low HDL, and small-dense LDL despite potentially acceptable LDL-C.

The consequence: elevated ApoB particle burden despite acceptable LDL cholesterol. The standard lipid panel misses this. ApoB captures it. Fasting insulin explains it. 5 / Solid

Endothelial Dysfunction

Insulin has direct endothelial effects at physiological levels, promoting nitric oxide production through PI3K pathway activation. In insulin resistance, this beneficial pathway is selectively impaired while the pro-inflammatory and vasoconstrictive effects of insulin are preserved. The result is endothelial dysfunction that is mechanistically driven by the insulin resistance state.

Studies of insulin-resistant individuals show reduced flow-mediated dilation compared to insulin-sensitive individuals matched for blood pressure and lipids. 4 / Promising

Visceral Fat Accumulation

Insulin is a fat-storage hormone. Chronic hyperinsulinemia promotes visceral fat deposition preferentially. Visceral fat is metabolically active: it releases free fatty acids into the portal circulation, produces inflammatory cytokines, and drives the insulin resistance that produced it in the first place. This is the self-perpetuating cycle that connects insulin resistance, visceral fat, inflammation, and cardiovascular risk.

The Cardiovascular Evidence

Prospective Cohort Data

The relationship between insulin resistance and cardiovascular events has been documented in multiple large prospective cohorts. The Insulin Resistance Atherosclerosis Study (IRAS), a multicenter prospective study, documented that insulin resistance was independently associated with carotid intima-media thickness progression, a marker of subclinical atherosclerosis, independent of traditional cardiovascular risk factors. 4 / Promising (Wagenknecht et al. 1997, Arteriosclerosis)

The METSIM (METabolic Syndrome In Men) study, following Finnish men over years, found that elevated fasting insulin independently predicted cardiovascular events after adjustment for traditional risk factors including glucose, lipids, and blood pressure. This study is methodologically important because it separated the contribution of fasting insulin from that of glucose, confirming that insulin resistance, not just dysglycemia, carries independent cardiovascular risk. 4 / Promising

Mendelian Randomization

Mendelian randomization studies using genetic variants associated with insulin resistance have confirmed causal directionality: genetic predisposition to higher fasting insulin is causally associated with higher cardiovascular risk, independent of the glucose phenotype. This is the causal evidence standard, and it supports insulin resistance as an independent cardiovascular risk driver. 4 / Promising

The Measurement Gap

Fasting insulin is not a new test. It has been available at standard clinical labs for decades. The reason it is absent from standard preventive cardiovascular evaluation is not lack of availability. It is the absence of a pharmacological treatment for insulin resistance that does not already address glucose (metformin was the primary pharmaceutical option, and it is indicated for prediabetes/diabetes, not for insulin resistance with normal glucose).

This reasoning, that there is nothing to prescribe, has discouraged measurement. It conflates diagnosis with pharmaceutical intervention. The interventions for insulin resistance that have the strongest evidence are behavioral: aerobic exercise, carbohydrate modulation, sleep restoration, and visceral fat reduction. These interventions do not require a prescription. They require a measurement that motivates the behavior change.

Reference Ranges and Clinical Targets

Most US laboratory reference ranges for fasting insulin list normal as below 17 to 25 uIU/mL. These are population distribution ranges in a metabolically burdened population. They should not be used as clinical targets.

Clinical interpretation framework based on the research literature:

HOMA-IR (calculated from fasting insulin and glucose) provides additional clinical context. Above 2.0 is borderline; above 2.9 is consistent with metabolic syndrome; above 5.0 is severe.

What the Measurement Changes

A fasting insulin result changes four clinical decisions:

Lipid management: High fasting insulin predicts ApoB discordance from LDL. If insulin is elevated and LDL is acceptable, ApoB should be measured to confirm the particle burden.

Blood pressure management: Insulin-mediated hypertension may respond better to lifestyle and specific drug classes than to others. The pathophysiology informs the treatment.

Statin indication: The metabolic phenotype associated with elevated insulin and discordant ApoB may indicate statin therapy before the standard lipid-based indications are met.

Behavioral intervention prioritization: A number that is elevated but reversible is motivating in a way that vague metabolic risk is not. The measurement creates the clinical conversation that behavior change requires.

The Exercise Effect: Why Aerobic Training Changes Insulin Sensitivity

Aerobic exercise is the most potent non-pharmacological intervention for insulin resistance, and the mechanism explains why it works at a level that dietary changes alone cannot fully replicate.

Skeletal muscle contraction activates glucose transporter type 4 (GLUT4) translocation to the cell surface through an AMP-kinase pathway that is entirely independent of insulin signaling. The practical meaning of this: exercising muscle takes up glucose without needing insulin to open the door. During a session of moderate-intensity aerobic exercise, contracting muscle accounts for the majority of whole-body glucose disposal, driven by AMP-kinase rather than the impaired insulin receptor pathway. The insulin resistance does not block this route.

The effect extends well beyond the exercise session itself. After a single bout of moderate-intensity aerobic exercise, insulin sensitivity in skeletal muscle remains elevated for 24 to 48 hours. The muscle has been primed to respond to insulin more efficiently during this window. Repeated sessions before the window closes prevent the return to baseline. After 8 weeks of consistent aerobic training, baseline GLUT4 expression in skeletal muscle increases by 20 to 50 percent, producing a sustained structural improvement in insulin sensitivity that reduces fasting insulin at rest.

The exercise prescription with the strongest evidence for insulin resistance is 150 minutes per week of moderate-intensity aerobic exercise, including brisk walking, cycling, and jogging, combined with resistance training at least twice per week. Resistance training builds the muscle mass that serves as the primary reservoir for glucose disposal. More muscle mass means more GLUT4-equipped tissue available to clear glucose with each meal.

Dela and colleagues demonstrated that 10 weeks of aerobic training reduced fasting insulin by approximately 25 percent in men with type 2 diabetes. The insulin-resistant man without diabetes sits earlier on the same continuum, and the mechanism is identical. The GLUT4 response is not diabetes-specific; it is a feature of skeletal muscle physiology that applies as long as muscle is present and contracting. 5 / Solid

Sleep and Insulin Resistance: The Night Shift Nobody Counts

Sleep restriction is a direct cause of insulin resistance, and the dose-response relationship is clinically relevant at exposures that most men consider ordinary.

Van Cauter and colleagues at the University of Chicago conducted controlled sleep restriction studies in previously healthy adults, limiting sleep to 5 to 6 hours per night for one week. The results: insulin sensitivity declined by 25 to 40 percent, with corresponding increases in fasting insulin. These were healthy subjects with no baseline metabolic dysfunction, and one week of modest sleep restriction was sufficient to produce a measurable insulin resistance state.

The mechanism operates through two primary pathways. First, sleep restriction elevates morning cortisol. Cortisol is a counter-regulatory hormone: it promotes hepatic glucose production and reduces peripheral insulin sensitivity as part of its normal function during stress response. When sleep is short, this cortisol signal is chronically elevated at times when it should be receding. The result is sustained hepatic glucose output and blunted peripheral insulin action. Second, short sleep activates the sympathetic nervous system. Sympathetic activation further impairs glucose metabolism through catecholamine-mediated suppression of insulin secretion and reduction of peripheral glucose uptake.

The man sleeping 5 to 6 hours and unable to explain why his metabolic markers are moving in the wrong direction despite a disciplined diet and consistent exercise is missing a central piece of the system. Sleep is not a recovery variable separate from metabolic management. It is a primary input into the hormonal environment that determines insulin sensitivity.

Restoring 7 to 8 hours per night can reduce fasting insulin by a clinically meaningful amount within weeks. The evidence for this reversal is less well-documented than the restriction studies, but the mechanism supports it. When cortisol normalizes and sympathetic tone decreases, the two primary drivers of sleep-mediated insulin resistance are removed. 4 / Promising

Carbohydrate Composition: Which Dietary Change Has the Strongest Evidence

Not all reductions in carbohydrate intake produce equivalent effects on fasting insulin. The dietary change with the most consistent evidence is specific: it targets the type of carbohydrate, not simply the quantity.

Rapidly digested refined carbohydrates, including white bread, white rice, sugar-sweetened beverages, and processed foods with added sugar, produce large postprandial glucose excursions. A large glucose excursion requires a large insulin secretory response to clear it. Repeated large insulin responses over years do two things: they accelerate beta cell exhaustion from chronic high-volume secretory demand, and they sustain the elevated circulating insulin that drives peripheral resistance through receptor downregulation and post-receptor signaling impairment.

The dietary intervention with the strongest evidence replaces refined carbohydrates with slowly digested alternatives, including legumes, non-starchy vegetables, and whole grains, while maintaining caloric balance. This flattens the postprandial glucose curve, reduces the required insulin secretory response, and over time reduces both fasting insulin and HOMA-IR.

The PREDIMED trial (Estruch et al.) compared Mediterranean dietary patterns against a low-fat control diet in a large randomized cohort. Mediterranean diet participants showed significant reductions in fasting insulin and HOMA-IR at 12 months. The Mediterranean pattern is not a low-carbohydrate diet; it is a low-refined-carbohydrate diet that replaces processed starches and sugars with legumes, olive oil, nuts, and vegetables. The mechanism aligns directly with the postprandial insulin reduction model.

Very low carbohydrate diets, defined as below 50 grams per day, reduce fasting insulin more rapidly in the short term by eliminating most of the postprandial glucose stimulus. The short-term data is consistent. The long-term adherence data is weaker, and the reduction in fasting insulin in adherent individuals on moderate carbohydrate diets of high quality approaches the same endpoint over a longer timeframe.

For most men, dietary carbohydrate quality matters more than quantity. Removing refined carbohydrates while keeping complex carbohydrates produces meaningful and sustainable improvements in fasting insulin without requiring extreme restriction. 4 / Promising

Three Actions

1. Ask for fasting insulin at your next morning lab draw. The conversation is one sentence: “I would like fasting insulin added to my metabolic panel.”

2. Calculate your HOMA-IR when you have both fasting insulin and fasting glucose: (insulin × glucose in mmol/L) / 22.5. A result above 2.0 warrants clinical discussion.

3. If your result is above 10, bring it to your physician with these questions: “Does this change my ApoB interpretation? Does this change my lipid management plan? What behavioral changes have the strongest evidence for reducing fasting insulin specifically?”

This paper is educational and does not constitute medical advice. Discuss your individual clinical situation with your physician.